Genmab (GMAB) Q2 2026 earnings review
Top-Line Surges, But Merus Debt Bites the Bottom Line
Genmab posted an impressive 25% YoY revenue growth in Q2 to $1,155M, driven by DARZALEX royalties and a 45% surge in global EPKINLY sales. However, management's touting of an 18% adjusted operating profit growth masks a harsher GAAP reality: Q2 Net Income fell 10% YoY, and H1 Net Income collapsed 33%. The culprit is the massive $5.5B debt taken on for the Merus acquisition, which generated $174M in H1 interest expenses, alongside $77M in integration costs. Despite the severe earnings drag, the commercial engine is firing on all cylinders. Guidance for 2026 revenue and adjusted operating profit was raised, reflecting immense confidence ahead of a catalyst-heavy Q4 featuring six pivotal Phase 2/3 readouts.
🐂 Bull Case
With crucial interim readouts for EPKINLY (1L DLBCL) and Petosemtamab (1L HNSCC) arriving in Q4 2026, positive data will unlock multibillion-dollar addressable markets and set up a wave of 2027 launches.
DARZALEX royalties grew 17% in Q2 to $744M, providing a stable, high-margin cash flow stream to fund aggressive R&D and SG&A expansion.
🐻 Bear Case
The $5.5B Merus acquisition is taking a heavy toll. H1 interest expenses of $174M and integration costs of $77M crushed GAAP profitability and operating cash flows, significantly slowing the path to deleveraging.
The entire 2027 growth narrative hinges on Q4 2026 readouts. After the previous EPCORE DLBCL-1 OS miss, any failure in the upcoming interims would fundamentally damage Genmab's long-term valuation.
⚖️ Verdict: ⚪
Hold. The operational momentum is undeniable, and the raised guidance points to strong top-line visibility. However, the heavy debt burden and the binary nature of the upcoming Q4 clinical readouts demand caution until the data is public.
Key Themes
EPKINLY Expanding its Footprint
Global net sales of EPKINLY/TEPKINLY surged 45% YoY in Q2 to $175M. The growth is fueled by strong uptake in community practices (over 90% of key customers ordering for 2+ sites) and a highly successful launch in 2L Follicular Lymphoma. A positive interim readout for 1L DLBCL in Q4 2026 could exponentially expand its market.
The Financial Cost of the Merus Acquisition
Management highlights adjusted operating profit (+18% YoY in H1), completely excluding the massive financial burden of the Merus acquisition. In reality, H1 GAAP Net Income fell 33%. The drag includes $174M in borrowing interest, $43M in debt fee amortization, and $77M in integration charges. Operating cash flow cratered from $349M to just $54M in H1 due to $191M in interest payments. Genmab is highly leveraged, and these costs will pressure the bottom line for years.
Petosemtamab Broadening Beyond HNSCC
Genmab announced the initiation of two Phase 3 trials for petosemtamab in 1L and 2L colorectal cancer (CRC). This significantly increases the Total Addressable Market for the asset beyond its core Head & Neck focus. Combined with Q4 2026 interims for 1L HNSCC, peto is rapidly becoming a multi-indication cornerstone of Genmab's pipeline.
DARZALEX Cash Engine Continues to Print
DARZALEX royalties remain the financial bedrock. J&J's underlying net sales for DARZALEX grew 21% in H1 to $8.17B. Corresponding royalties to Genmab grew 20% to $1.3B in H1 ($744M in Q2). This recurring, high-margin revenue is essential to offset the heavy R&D burn required to launch Genmab's proprietary pipeline.
AbbVie and Chugai Litigation Overhangs
While AbbVie dropped its ITC complaint regarding Rina-S trade secrets, it intends to pursue the case in US district court. Meanwhile, Chugai expanded its patent infringement lawsuits in Japan against EPKINLY. While Genmab categorically refutes these claims, ongoing legal battles create unpredictable long-term IP risks and drive up SG&A litigation expenses.
Rina-S Poised to Challenge the ADC Landscape
Genmab expects Q4 2026 readouts for both Phase 2 and Phase 3 trials of Rina-S in platinum-resistant ovarian cancer (PROC). With a high response rate (>50%) and long durability linked to a very low discontinuation rate, Genmab believes it has a best-in-class Topo 1 ADC that works across the spectrum of folate receptor alpha expression.
Other KPIs
Decelerating violently. Collapsed from $349M in H1 2025. This $295M drop is primarily due to a $191M hit in interest paid on the new debt, alongside massive jumps in R&D and commercialization spending for late-stage assets.
Accelerating. Up 42% YoY ($144M in Q2 25). Driven by aggressive global commercialization build-outs for Rina-S and petosemtamab, Merus integration overhead, and mounting litigation fees.
Reversing. Down drastically from 20.3% in H1 2025. This artificially propped up Net Income, resulting from deferred tax asset recognition linked to the Merus integration. Management expects the rate to normalize over the next 12-18 months, which will create a future headwind for GAAP net profit.
Guidance
Accelerating. The midpoint ($4,425M) was raised from the previous $4,230M, implying roughly 19% YoY growth from FY25 actuals ($3,720M). Half of the upgrade stems from DARZALEX outperformance, and the other half from EPKINLY.
Accelerating. Raised midpoint to $1,225M from $1,150M. Indicates that the core business generates excellent operating leverage despite a slight 2% upward revision in adjusted operating expenses ($2,880M midpoint).
Accelerating. Raised midpoint to $3,687M from $3,563M. Driven directly by the unrelenting growth of DARZALEX globally.
Key Questions
EPKINLY 1L DLBCL Interim Ramifications
If the EPCORE DLBCL-2 trial fails to meet the efficacy bar at the upcoming Q4 interim analysis, will the study continue to the final analysis, or would it prompt a strategic reprioritization?
Debt Servicing vs Shareholder Returns
With operating cash flows taking a severe hit from $191M in interest payments this half, how does the current debt servicing cost impact the timeline for achieving the sub-3x gross leverage target, and will it restrict future share buybacks?
Petosemtamab Competitive Efficacy Bar
As amivantamab aggressively pursues accelerated approval in HNSCC, what specific objective response rates or durability metrics in the Q4 Peto 1L interim will be required to definitively prove the 'best-in-class' claim?
AbbVie Litigation Escalation
With the ITC complaint dropped but the district court case resuming, is there a contingency plan or financial provisioning if the Rina-S trade secret allegations advance to a trial phase?